Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women.

× No keyword cloud information.

29 in total

Review 1. Parathyroid hormone analogues in the treatment of osteoporosis.

Authors: Marius E Kraenzlin; Christian Meier
Journal: Nat Rev Endocrinol Date: 2011-07-12 Impact factor: 43.330

Review 2. Osteoanabolic and dual action drugs.

Authors: Gaia Tabacco; John P Bilezikian
Journal: Br J Clin Pharmacol Date: 2019-04-03 Impact factor: 4.335

3. Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model.

Authors: N Ersan; L J van Ruijven; A L J J Bronckers; V Olgaç; D Ilgüy; V Everts
Journal: Dentomaxillofac Radiol Date: 2013-10-29 Impact factor: 2.419

Review 4. Parathyroid hormone as an anabolic skeletal therapy.

Authors: Mishaela R Rubin; John P Bilezikian
Journal: Drugs Date: 2005 Impact factor: 9.546

5. The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation.

Authors: Sunday A Shoyele; Neeraj Sivadas; Sally-Ann Cryan
Journal: AAPS PharmSciTech Date: 2011-01-27 Impact factor: 3.246

6. Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.

Authors: Gerdi Tuli; Raffaele Buganza; Daniele Tessaris; Silvia Einaudi; Patrizia Matarazzo; Luisa de Sanctis
Journal: Endocrine Date: 2019-11-08 Impact factor: 3.633

7. Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.

Authors: S Kimura; M Saito; Y Kida; A Seki; Y Isaka; K Marumo
Journal: Osteoporos Int Date: 2016-10-29 Impact factor: 4.507

Review 8. Clinical update on teriparatide.

Authors: Elizabeth File; Chad Deal
Journal: Curr Rheumatol Rep Date: 2009-07 Impact factor: 4.592

9. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

Authors: J-M Kaufman; E Orwoll; S Goemaere; J San Martin; A Hossain; G P Dalsky; R Lindsay; B H Mitlak
Journal: Osteoporos Int Date: 2004-08-18 Impact factor: 4.507

10. Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen.

Authors: Yugal Behl; Michelle Siqueira; Javier Ortiz; Jingchao Li; Tesfahun Desta; Dan Faibish; Dana T Graves
Journal: J Immunol Date: 2008-12-15 Impact factor: 5.422